Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma [Emerging Investigators]

Conclusions:
In patients with metastatic renal cell carcinoma, sunitinib resulted in early, significant increases in blood pressure, arterial stiffness, and resistive and pulsatile load within 3.5 weeks of treatment. Baseline vascular function parameters were associated with worsening diastolic but not systolic function.

Source: Circulation: Heart Failure - March 16, 2018 Category: Cardiology Authors: Catino, A. B., Hubbard, R. A., Chirinos, J. A., Townsend, R., Keefe, S., Haas, N. B., Puzanov, I., Fang, J. C., Agarwal, N., Hyman, D., Smith, A. M., Gordon, M., Plappert, T., Englefield, V., Narayan, V., Ewer, S., ElAmm, C., Lenihan, D., Ky, B. Tags: Heart Failure, Hypertension Emerging Investigators Source Type: research